Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX + Cetuximab + Cyclophosphamide in Pancreatic Cancer
NCT00305760Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2005
- Primary completion
- Mar 2009
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GVAX pancreatic cancer vaccine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux at 7 months. Started Dec 2005; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00305760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305760.